A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase

Enrolling

Phase 1

Conditions

Lung Cancer

Non Small Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

Treatments

Diagnostic Test: PET/CT Scan

Drug: Zirconium Zr 89 crefmirlimab berdoxam

Study type

Interventional

Funder types

Other

Identifiers

NCT06863233

24-369

Details and patient eligibility

About

The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells

Enrollment

5 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient must be 18 years of age or older at the time of signing the informed consent.
Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer
Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.
Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.

Exclusion criteria

Pregnant or breastfeeding women
Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)